| JURČEK, Tomáš, Filip RÁZGA, Petra MAZANCOVÁ, Milena MUSILOVÁ, Dana DVOŘÁKOVÁ, Marek BORSKÝ, Daniela ŽÁČKOVÁ, Blanka DOBEŠOVÁ, Lukáš SEMERÁD, Jiří MAYER and Zdeněk RÁČIL. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2014, vol. 55, No 8, p. 1915-1917. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2013.842988. |
Other formats:
BibTeX
LaTeX
RIS
@article{1217003,
author = {Jurček, Tomáš and Rázga, Filip and Mazancová, Petra and Musilová, Milena and Dvořáková, Dana and Borský, Marek and Žáčková, Daniela and Dobešová, Blanka and Semerád, Lukáš and Mayer, Jiří and Ráčil, Zdeněk},
article_location = {LONDON},
article_number = {8},
doi = {http://dx.doi.org/10.3109/10428194.2013.842988},
keywords = {BCR-ABL1; T315I; CD34+; chronic myeloid leukemia},
language = {eng},
issn = {1042-8194},
journal = {LEUKEMIA & LYMPHOMA},
title = {Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia},
volume = {55},
year = {2014}
}
TY - JOUR
ID - 1217003
AU - Jurček, Tomáš - Rázga, Filip - Mazancová, Petra - Musilová, Milena - Dvořáková, Dana - Borský, Marek - Žáčková, Daniela - Dobešová, Blanka - Semerád, Lukáš - Mayer, Jiří - Ráčil, Zdeněk
PY - 2014
TI - Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia
JF - LEUKEMIA & LYMPHOMA
VL - 55
IS - 8
SP - 1915-1917
EP - 1915-1917
PB - INFORMA HEALTHCARE
SN - 10428194
KW - BCR-ABL1
KW - T315I
KW - CD34+
KW - chronic myeloid leukemia
N2 - Th e detection of BCR – ABL1 kinase domain (KD) mutations is frequently associated with resistance to tyrosine kinase inhibitors (TKIs), which results in an impaired prognosis for patients with chronic myeloid leukemia (CML) [1]. Early detection of these mutations can potentially lead to early therapeutic intervention and optimization of an ongoing treatment strategy. Considering the hematopoiesis hierar- chy, it is expected that BCR – ABL1 mutation clones expand directly from hematopoietic stem cells or early progenitor cells [2]. It has already been reported that BCR – ABL1 KD mutations were detected in these cells before they occurred in bone marrow (BM) or peripheral blood (PB) [3]. Particu- lar focus should be given to the T315I mutation, which is resistant to all approved TKIs (imatinib, nilotinib and dasa- tinib) [4,5], meaning that early detection of this key BCR – ABL1 KD mutation in “ source ” cells could have potential clinical benefits.
ER -
JURČEK, Tomáš, Filip RÁZGA, Petra MAZANCOVÁ, Milena MUSILOVÁ, Dana DVOŘÁKOVÁ, Marek BORSKÝ, Daniela ŽÁČKOVÁ, Blanka DOBEŠOVÁ, Lukáš SEMERÁD, Jiří MAYER and Zdeněk RÁČIL. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2014, vol.~55, No~8, p.~1915-1917. ISSN~1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2013.842988.
|
